<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185328</url>
  </required_header>
  <id_info>
    <org_study_id>91436</org_study_id>
    <secondary_id>309367</secondary_id>
    <nct_id>NCT00185328</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Angeliq in Thai Women</brief_title>
  <official_title>A Multi-Center, Open-Label, Non-Comparative Study Investigating the Efficacy and Tolerability of AngeliqÂ® in Postmenopausal Thai Women With Vasomotor Symptoms Over Three 28-Day Treatment Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, and efficacy of Angeliq in Thai post menopausal women
      with hot flushes and other climacteric symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
      renamed to Bayer Schering Pharma AG, Germany.

      Bayer Schering Pharma AG, Germany is the sponsor of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The relative change in the frequency of hot flushes</measure>
    <time_frame>At baseline, week 4, 8, 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in intensity of hot flushes</measure>
    <time_frame>At baseline, week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relative change in frequency of hot flushes</measure>
    <time_frame>At baseline, week 4, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in intensity of hot flushes</measure>
    <time_frame>At baseline, week 4, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportions of subjects with urogenital symptoms</measure>
    <time_frame>At baseline, week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding pattern</measure>
    <time_frame>At baseline, week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>Collection of AE throughout the study period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Postmenopause</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol/DRSP (Angeliq, BAY86-4891)</intervention_name>
    <description>1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women with hot flushes

        Exclusion Criteria:

          -  Women with a contraindication for Hormone Replacement Therapy (HRT)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Thailand</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product</description>
  </link>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>December 11, 2008</last_update_submitted>
  <last_update_submitted_qc>December 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Therapeutic Area Head</name_title>
    <organization>Bayer Schering Pharma AG</organization>
  </responsible_party>
  <keyword>Postmenopause</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

